214 related articles for article (PubMed ID: 24980613)
1. Prognostic value of RASSF1 promoter methylation in prostate cancer.
Daniunaite K; Jarmalaite S; Kalinauskaite N; Petroska D; Laurinavicius A; Lazutka JR; Jankevicius F
J Urol; 2014 Dec; 192(6):1849-55. PubMed ID: 24980613
[TBL] [Abstract][Full Text] [Related]
2. Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer.
Daniūnaitė K; Berezniakovas A; Jankevičius F; Laurinavičius A; Lazutka JR; Jarmalaitė S
Medicina (Kaunas); 2011; 47(3):147-53. PubMed ID: 21822036
[TBL] [Abstract][Full Text] [Related]
3. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
5. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease.
Singal R; Ferdinand L; Reis IM; Schlesselman JJ
Oncol Rep; 2004 Sep; 12(3):631-7. PubMed ID: 15289848
[TBL] [Abstract][Full Text] [Related]
6. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.
Cottrell S; Jung K; Kristiansen G; Eltze E; Semjonow A; Ittmann M; Hartmann A; Stamey T; Haefliger C; Weiss G
J Urol; 2007 May; 177(5):1753-8. PubMed ID: 17437806
[TBL] [Abstract][Full Text] [Related]
7. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
Bastian PJ; Ellinger J; Wellmann A; Wernert N; Heukamp LC; Müller SC; von Ruecker A
Clin Cancer Res; 2005 Jun; 11(11):4097-106. PubMed ID: 15930345
[TBL] [Abstract][Full Text] [Related]
9. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy.
Bastian PJ; Ellinger J; Heukamp LC; Kahl P; Müller SC; von Rücker A
Eur Urol; 2007 Mar; 51(3):665-74; discussion 674. PubMed ID: 16956712
[TBL] [Abstract][Full Text] [Related]
11. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
[TBL] [Abstract][Full Text] [Related]
12. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
[TBL] [Abstract][Full Text] [Related]
13. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia.
Kang GH; Lee S; Lee HJ; Hwang KS
J Pathol; 2004 Feb; 202(2):233-40. PubMed ID: 14743506
[TBL] [Abstract][Full Text] [Related]
14. DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer.
Moritz R; Ellinger J; Nuhn P; Haese A; Müller SC; Graefen M; Schlomm T; Bastian PJ
Anticancer Res; 2013 Dec; 33(12):5249-54. PubMed ID: 24324057
[TBL] [Abstract][Full Text] [Related]
15. Gene promoter methylation in prostate tumor-associated stromal cells.
Hanson JA; Gillespie JW; Grover A; Tangrea MA; Chuaqui RF; Emmert-Buck MR; Tangrea JA; Libutti SK; Linehan WM; Woodson KG
J Natl Cancer Inst; 2006 Feb; 98(4):255-61. PubMed ID: 16478744
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.
Haldrup C; Mundbjerg K; Vestergaard EM; Lamy P; Wild P; Schulz WA; Arsov C; Visakorpi T; Borre M; Høyer S; Orntoft TF; Sørensen KD
J Clin Oncol; 2013 Sep; 31(26):3250-8. PubMed ID: 23918943
[TBL] [Abstract][Full Text] [Related]
17. IGFBP7 promoter methylation and gene expression analysis in prostate cancer.
Sullivan L; Murphy TM; Barrett C; Loftus B; Thornhill J; Lawler M; Hollywood D; Lynch T; Perry AS
J Urol; 2012 Oct; 188(4):1354-60. PubMed ID: 22906661
[TBL] [Abstract][Full Text] [Related]
18. Global methylation profiling for risk prediction of prostate cancer.
Mahapatra S; Klee EW; Young CY; Sun Z; Jimenez RE; Klee GG; Tindall DJ; Donkena KV
Clin Cancer Res; 2012 May; 18(10):2882-95. PubMed ID: 22589488
[TBL] [Abstract][Full Text] [Related]
19. MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
Henrique R; Jerónimo C; Hoque MO; Nomoto S; Carvalho AL; Costa VL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1274-8. PubMed ID: 15894685
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.
Padar A; Sathyanarayana UG; Suzuki M; Maruyama R; Hsieh JT; Frenkel EP; Minna JD; Gazdar AF
Clin Cancer Res; 2003 Oct; 9(13):4730-4. PubMed ID: 14581343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
